Second generation proteasome inhibitors in multiple myeloma
| Autor: | Alessandro Gozzetti, Corrado Zuanelli Brambilla, Santina Sirianni, Monica Bocchia, Veronica Candi, Giulia Papini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Threonine
Cancer Research Myeloma 02 engineering and technology Pharmacology Blood–brain barrier 01 natural sciences Bortezomib Carfilzomib Myeloma New proteasome inhibitors Oprozomib Ixazomib Central Nervous System Neoplasms Bortezomib chemistry.chemical_compound Lactones New proteasome inhibitors Drug Discovery medicine Animals Humans Pyrroles Multiple myeloma business.industry Drug discovery 010401 analytical chemistry Carfilzomib 021001 nanoscience & nanotechnology medicine.disease Boronic Acids 0104 chemical sciences medicine.anatomical_structure Proteasome chemistry Proteasome inhibitor Molecular Medicine Oprozomib Neoplasm Recurrence Local 0210 nano-technology business Multiple Myeloma Oligopeptides Proteasome Inhibitors medicine.drug |
| Popis: | Bortezomib was the first proteasome inhibitor (PI) discovered and demonstrated great efficacy in myeloma, both in vitro and in patients. However, still many patients ultimately relapse and there is the need for novel therapies. A second generation of PI have been discovered, potentially more effective ands some also orally administered. Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies. Ixazomib is an oral compound that has been introduced recently in the therapeutic spectrum. Novel agents such as Marizomib seem promising in the fact that can also pass through the blood brain barrier and maybe effective also in CNS muyeloma. This review focus on all proteasome inhibitors available in clinics and the new ones coming soon. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|